comparemela.com

Latest Breaking News On - Post venetoclax patients - Page 1 : comparemela.com

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the.

United statesSouth san franciscoDavid rosenJorgee cortesRaul rodriguezCecilf whitaker jrRigel pharmaceuticals incAmerican cancer societyEuropean medicines agencyExchange commissionGeorgia cancer centerPrnewswire rigel pharmaceuticals incScholar chairFull prescribing informationRigel pharmaceuticalsAmerican cancer

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®.

United statesSouth san franciscoJorgee cortesCecilf whitaker jrDavid rosenRaul rodriguezExchange commissionDrug administrationAmerican cancer societyGeorgia cancer centerEuropean hematology associationPrnewswire rigel pharmaceuticals incRigel pharmaceuticals incScholar chairPost venetoclax patientsPractice guidelines

vimarsana © 2020. All Rights Reserved.